Please assess the completion status of the following clinical trial:

Trial Title: Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria - Part II: (HCV Infected Patients)~* Adult males and females aged 18 to 64 years of age~* Chronic HCV infection, defined as virological diagnosis of HCV for at least six months with detectable serum HCV-RNA levels \>100,000 IU/mL by an HCV-RNA PCR assay on two occasions at least one week apart within 4 weeks prior to study drug administration~* Signed and dated written informed consent form~* Negative serum ß-HCG (pregnancy) test 24 hours prior to initial dose of AVI-4065 Injection for females of childbearing potential, or post-menopausal and amenorrheic for 2 years, or surgically sterilized for at least one year~* Willing to abstain from alcohol from the beginning of study entry through Day 28 of the study~* Willing to participate in all study activities (including the ability to safely self-inject study drug subcutaneously) and all study requirements (including effective contraception) during study period~Exclusion Criteria - Part II (HCV Patients):~* Hematology, coagulation, serum chemistry, and urinalysis laboratory test values \>2 times upper limits of normal or anemia (hemoglobulin \<11 g/dL), leukopenia (total white blood count \<3,000/ µL or total neutrophils \<1,500/ µL) or thrombocytopenia (platelets \<100,000/ µL)~* Decompensated or severe liver disease, defined as cirrhotic patients with a Child-Pugh score of ≥ 7~* Encephalopathy or altered mental status of any etiology~* Any neoplasm, including hepatocellular carcinoma~* Decompensated renal disease (e.g., serum creatinine \>2.5 or on a dialysis program)~* Positive HIV-1 or HIV-2 serology~* Positive Hepatitis B Surface Antigen (HBsAg) or Hepatitis B Core Antibody (HBcAb) status~* Participation in any interventional clinical trial within previous 6 months~* Organ transplant recipient (solid or hematopoietic)~* Use of interferons and ribavirin or experimental HCV treatment within past 6 months~* Use of non-steroidal anti-inflammatory agents (e.g., ibuprofen, naproxen or COX-2 inhibitors) that exceeds 2 days per week of the recommended daily dosing or usage that exceeds 5 grams/week.~* Use of acetaminophen within 15 days of enrollment and throughout Day 28 of the study~* Body Mass Index (BMI) \> 35~* Pregnant or nursing female~* Active serious or poorly controlled chronic illness~* History of poor compliance with health and treatment regimens~* Use of herbal or homeopathic products, illicit drugs, statins, corticosteroids, immunosuppressives, or cytotoxic agents within 90 days of first dose of study drug~* Use of drugs with potential hepatotoxicity, e.g., oral antifungals or oral glucophage inhibitors~* Unwilling to participate in any study activity (including to safely self-inject study medication subcutaneously) and complete any study requirement (including effective contraception) during study period and competition of any study visit~* Investigator opinion of unsuitability

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy